eligibility_summary
Step 1: MM with SD+ at day 80–110 post ide‑cel, AEs ≤G1 (fatigue/alopecia ok), ≥4 prior lines incl PI, IMiD, anti‑CD38, prior iberdomide allowed if not refractory, no post–ide‑cel MM therapy (brief steroids ok, off >30 d by C1D1). Age ≥18, ECOG ≤2, ANC ≥1500, Plt ≥75k, CrCl ≥30, bili ≤1.5×ULN, AST/ALT ≤3×ULN. Not pregnant/nursing, contraception. Controlled HIV/HBV/HCV allowed, exclude POEMS, infection, iberdomide allergy, dysphagia, switch/washout strong CYP3A4.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06179888: Randomized phase 2 trial testing iberdomide maintenance vs observation after idecabtagene vicleucel (ide‑cel) CAR‑T in multiple myeloma. Drugs/interventions: • Iberdomide (CC‑220): oral small‑molecule CELMoD (immunomodulatory). Mechanism: binds cereblon E3 ligase, induces degradation of IKZF1/IKZF3, lowering IRF4/MYC in myeloma cells, with direct anti‑myeloma effects and immune stimulation (enhanced T‑cell/NK‑cell activation, increased IL‑2), intended to augment CAR‑T function/persistence. • Ide‑cel: autologous BCMA‑directed CAR‑T cell therapy, CAR‑T recognizes BCMA on plasma cells to mediate cytotoxicity. Targets/pathways: BCMA on myeloma cells (CAR‑T), cereblon‑IKZF pathway, T‑cell and NK‑cell activation, endpoints include PFS, MRD conversion, CAR‑T persistence, and immunophenotype. Observation arm involves monitoring only.